Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesNarrative Review: Statin-Related Myopathy
Annals of Internal Medicine, 06/16/09
Joy TR et al. - Statin-related myopathy comprises myalgias, myositis, and rhabdomyolysis. Myalgias can affect up to 10% of persons prescribed statins, whereas rhabdomyolysis is rare. The mechanisms responsible for statin-related myopathy are unclear but may include decreased levels of coenzyme Q10, decreased bioavailability of isoprenoids, or mitochondrial dysfunction. Risk factors for myopathy include history of myopathy while receiving another lipid-lowering agent, family history of statin-related myopathy, high-dose statin therapy, increased age, female sex, and use of medications metabolized through cytochrome P450 3A4. Assessment of statin-related myopathy includes a search for other causes of creatine kinase elevation and myopathy. Management of statin-related myopathy can include switching agents or use of fluvastatin, low-dose rosuvastatin, nondaily dosing, and ezetimibe or bile acid–binding resins.
Related Articles
Inflammatory myopathies
Zeitschrift für Rheumatologie, 10/07/09
Relevance Score: 46%
Muscle carnitine deficiency: adult onset lipid storage myopathy with sensory neuropathy
Neurological Sciences, 10/07/09
Relevance Score: 45%
Vaccines as a trigger for myopathies
Lupus, 11/16/09
Relevance Score: 44%
Immune-mediated necrotizing myopathy associated with statins
Muscle & Nerve, 10/12/09
Relevance Score: 43%
Skeletal muscle cell MHC I expression: Implications for statin-induced myopathy
Muscle & Nerve, 10/12/09
Relevance Score: 43%
Today in Adverse Drug Reactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Continuation of Low-Dose Aspirin in Peptic Ulcer Bleeding. A Randomized Trial
Annals of Internal Medicine, 12/01/09
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
International Journal of Emergency Medicine, 12/01/09
Seliciclib in malignancies
Expert Opinion on Investigational Drugs, 11/30/09
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Vascular Health and Risk Management, 12/01/09
Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals
Expert Opinion on Investigational Drugs, 12/01/09
Continuation of Low-Dose Aspirin in Peptic Ulcer Bleeding. A Randomized Trial
Annals of Internal Medicine, 12/01/09
Sponsor
Article Search
Sponsor